ArticleAllergy2021
COVID-19 pandemic and allergen immunotherapy-an EAACI survey.
Article in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- The impact of public health emergencies on allergen immunotherapy practices: A cross-sectional study on COVID-19 and physicians' perspectives in China.Asia Pacific allergy · 2026Article
- RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.Journal of personalized medicine · 2024Article
- Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study.BMC infectious diseases · 2024Article
- Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies-Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce.Clinical and translational allergy · 2023Article
- Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients.The World Allergy Organization journal · 2023Article
- Does allergen immunotherapy impact the susceptibility and severity of COVID-19?Clinical and translational allergy · 2023Article
- A retrospective study regarding the influence of COVID-19 disease on asthma.BMC pulmonary medicine · 2023Article
- Clinical endpoints in allergen immunotherapy: State of the art 2022.Allergologie select · 2023Review
- Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022Article
- Allergen immunotherapy during the COVID-19 pandemic-A survey of the German Society for Allergy and Clinical Immunology.Clinical and translational allergy · 2022Article
- A bird's eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines.Allergy · 2022Review
- Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19.Asia Pacific allergy · 2022Article
- 111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases.Allergologie select · 2022Review
- Real-life data on inactivated COVID-19 vaccination in patients with subcutaneous allergen immunotherapy.Clinical and translational allergy · 2022Article
- Allergic patients during the COVID-19 pandemic-Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey.Clinical and translational allergy · 2022Article
- Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic.Allergy · 2022Article
- Real-life report of allergen immunotherapy management during the COVID-19 outbreak in France and Spain.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- Allergen Immunotherapy management during vaccinations: An international survey.The World Allergy Organization journal · 2021Article
- Recent advances and developments in COVID-19 in the context of allergic diseases.Clinical and translational allergy · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 20 institutions in 15 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.
methodsUnder the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey
results417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
conclusionsThis first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.